Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients - Pharmaceutical Technology

Qfitlia approved by FDA to treat haemophilia A or B - Pharmafile

The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran) as the first therapy in the US to treat haemophilia A or B, with or without inhibitors. The approval of the antithrombin-lowering (AT) drug was based on data from the ATLAS phase 3 studies that Sanofi conducted. Sanofi is an international pharma and healthcare […] The post Qfitlia approved by FDA to treat haemophilia A or B appeared first on Pharmafile.

Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients - Pharmaceutical Technology

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper hand.

The development of genetic testing has managed to avoid uncertainty in many families, especially in women who carry the disease, and better guide therapies.